切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2018, Vol. 12 ›› Issue (04) : 204 -211. doi: 10.3877/cma.j.issn.1674-0785.2018.04.004

所属专题: 文献

胃肠道肿瘤

原发性胃淋巴瘤临床病理特征及预后独立危险因素分析
杜楠1, 朱志1,(), 徐惠绵1   
  1. 1. 110001 沈阳,中国医科大学附属第一医院胃肠肿瘤外科
  • 收稿日期:2018-01-20 出版日期:2018-02-15
  • 通信作者: 朱志
  • 基金资助:
    国家自然科学基金(81302129)

Clinicopathological characteristics and prognostic factors of primary gastric lymphoma: a retrospective analysis of 53 cases

Nan Du1, Zhi Zhu1,(), Huimian Xu1   

  1. 1. Department of Gastrointestinal Oncological Surgery, the First Hospital of China Medical University, Shenyang 110000, China
  • Received:2018-01-20 Published:2018-02-15
  • Corresponding author: Zhi Zhu
  • About author:
    Corresponding author: Zhu Zhi, Email:
引用本文:

杜楠, 朱志, 徐惠绵. 原发性胃淋巴瘤临床病理特征及预后独立危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2018, 12(04): 204-211.

Nan Du, Zhi Zhu, Huimian Xu. Clinicopathological characteristics and prognostic factors of primary gastric lymphoma: a retrospective analysis of 53 cases[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(04): 204-211.

目的

分析原发性胃淋巴瘤(PGL)组织分型及围手术期相关因素对预后的影响。

方法

对中国医科大学附属第一医院胃肠肿瘤外科1988年9月至2011年7月期间收治的53例PGL患者的临床病理资料进行回顾性分析,通过Kaplan-Meier生存曲线计算累积生存率,采用Log-rank检验单因素分析和Cox模型多因素分析分析其临床特征及围手术期相关因素对预后的影响,并通过单因素分析法分析不同病理分型,其影响预后相关因素是否存在差异。

结果

53例PGL患者发病年龄21~78岁(平均年龄54岁,中位年龄58岁)。本组病例组织分型:黏膜相关淋巴组织淋巴瘤(MALT)占64.2%(34/53)、弥漫性大B细胞淋巴瘤(DLBCL)22.6%(12/53)。Ann Arbor临床分期:ⅠE期22例(41.5%,22/53)、ⅡE期19例(35.8%,19/53)、ⅢE期1例(1.9%,1/53)、ⅣE期10例(18.9%,10/53)。随访资料完整的53例患者中,1、3、5年生存率分别为81.1%、47.2%、32.1%,总体中位生存期为35个月。单因素分析显示:影响预后的相关因素中性别(P=0.021)、年龄(P=0.028)、肿瘤大小(P=0.004)、手术根治度(P<0.001)、侵犯脏器(P<0.001)、病理组织分型(P=0.006)、Ann Arbor分期(P=0.029)方面差异具有统计学意义;多因素分析显示:手术根治度(OR=3.611)、病变组织分型(OR=1.729)、Ann Arbor分期(OR=1.509)是影响预后的独立因素。影响MALT预后相关因素中性别(P=0.028)、手术根治度(P<0.001)、侵犯脏器(P<0.001)以及Ann Arbor分期(P=0.003)方面差异具有统计学意义。而DLBCL预后与患者胃肠道炎性病变、溃疡等良性疾病史存在相关性(P=0.003)。

结论

肿瘤根治度、侵犯脏器、原发性胃淋巴瘤的组织分型是影响原发性胃淋巴瘤预后的独立因素;患者性别、手术根治度、侵犯脏器、Ann Arbor分期与MALT的预后存在相关性;患者胃肠道疾病史与DLBCL预后存在相关性。

Objective

To analyze the clinical and pathological characteristics and prognostic factors of primary gastric lymphoma.

Methods

The clinical data of 53 patients with primary gastric lymphoma were retrospectively analyzed from September 1988 to July 2011 at the First Hospital of China Medical University. Kaplan-Meier analysis, Log-rank test, Cox regression analysis, and univariate analysis were used to examine whether there was a difference in prognostic factors in different pathological types.

Results

There were 34 males and 19 females, and their age was 21 to 78 years, with an average age of 54 years and a median age of 58 years. There were 4 cases of Hodgkin's lymphoma, 34 cases of mucosa-associated lymphoid tissue (MALT) lymphoma, 12 cases of diffuse large B-cell lymphoma (DCBCL), and 3 cases of lymphoid plasma cell lymphoma. The most common histological type was MALT lymphoma (64.2%), and most patients had Ann Arbor stages IE (41.5%) and IIE (31.7%) diseases. The 1-, 3-, and 5-year survival rates were 81.1%, 47.2%, and 32.1%, respectively. The median overall survival time was 35.0 months. Univariate analysis showed that gender (P=0.021), age (P=0.028), tumor size (P=0.004), tumor resection (P<0.001), organ invasion (P<0.001), histological type (P=0.006), and Ann Arbor stage (P=0.029) were significantly correlated with the prognosis. Multivariable analysis demonstrated that tumor resection (OR=3.611), histological type (OR=1.729), and Ann Arbor stage (OR=1.509) were independent prognostic factors. Moreover, the prognosis of MALT lymphoma was correlated with gender (P=0.028), tumor resection (P<0.001), organ invasion (P<0.001), and Ann Arbor stage (P=0.003). For DLBCL patients, chronic gastric disease were correlated with the prognosis (P=0.003).

Conclusion

Tumor resection, histological type, and Ann Arbor stage are independent prognostic factors. The prognosis of MALT lymphoma correlates with gender, tumor resection, organ invasion, and Ann Arbor stage. For DLBCL lymphoma patients, history of chronic gastric disease correlates with the prognosis.

表1 Ann Arbor胃淋巴瘤临床分期标准
表2 PGL预后影响因素的单因素分析
病例资料 构成比[%(例/例)] 1年生存率(%) 3年生存率(%) 5年生存率(%) χ2 P
性别 ? ? ? ? 5.313 0.021
? 64.2(34/53) 73.5 50.2 28.7 ? ?
? 35.8(19/53) 84.2 73.7 60.8 ? ?
年龄 ? ? ? ? 4.826 0.028
? ≥60岁 45.3(24/53) 66.7 49.2 32.8 ? ?
? <60岁 54.7(29/53) 86.2 67.3 53.5 ? ?
淋巴结检取总数 ? ? ? ? 0.007 0.935
? ≥20个 50.0(23/46) 82.6 59.0 38.2 ? ?
? <20个 50.0(23/46) 82.6 60.6 46.6 ? ?
淋巴结转移 ? ? ? ? 0.350 0.554
? 54.3(25/46) 80.0 54.9 39.9 ? ?
? 45.7(21/46) 81.0 65.4 46.8 ? ?
肿瘤位置 ? ? ? ? 0.084 0.994
? 上、上中 28.3(15/53) 73.3 55.6 33.3 ? ?
? 中、中下 24.5(13/53) 76.5 50.8 38.1 ? ?
? 下部 34.0(18/53) 77.8 60.0 46.7 ? ?
? 全胃 13.2(7/53) 71.4 57.1 42.9 ? ?
既往胃肠道疾病史 ? ? ? ? 0.579 0.447
? 24.5(13/53) 69.2 59.3 47.5 ? ?
? 75.5(40/53) 80.0 55.3 42.3 ? ?
病例资料 构成比[%(例/例)] 1年生存率(%) 3年生存率(%) 5年生存率(%) χ2 P
淋巴管瘤栓 ? ? ? ? 0.001 0.972
? 33.3(15/45) 80.0 52.4 39.3 ? ?
? 66.7(30/45) 80.0 59.4 45.4 ? ?
术后治疗 ? ? ? ? 0.233 0.629
? 19.6(10/51) 70.0 40.0 35.0 ? ?
? 80.4(41/51) 78.0 56.1 36.9 ? ?
胃切除范围 ? ? ? ? 2.421 0.298
? 胃近端切除 22.4(11/49) 72.7 50.9 38.2 ? ?
? 胃远端切除 51.0(25/49) 88.0 66.7 56.7 ? ?
? 全胃切除 26.5(13/49) 76.8 53.8 35.9 ? ?
手术根治度 ? ? ? ? 14.802 <0.001
? R0切除 71.4(35/49) 91.4 72.9 60.5 ? ?
? 姑息切除 28.6(14/49) 64.3 28.6 7.1 ? ?
侵犯脏器 ? ? ? ? 16.092 <0.001
? 32.0(16/50) 50.0 19.4 9.7 ? ?
? 68.0(34/50) 85.3 75.8 56.6 ? ?
肿瘤大小 ? ? ? ? 4.682 0.004
? ≥5.0 cm 43.8(21/48) 83.3 66.7 58.3 ? ?
? <5.0 cm 56.2(27/48) 82.1 73.7 49.9 ? ?
Ann Arbor分期 ? ? ? ? 9.323 0.029
? ⅠE期 41.5(22/53) 90.9 79.3 52.0 ? ?
? ⅡE期 37.7(20/53) 75.0 44.0 37.7 ? ?
? ⅢE期 1.9(1/53) - - - ? ?
? ⅣE期 18.9(10/53) 40.0 30.0 20.0 ? ?
组织分型 ? ? ? ? 12.872 0.006
? MALT 64.2(34/53) 82.4 76.0 58.8 ? ?
? HL 7.5(4/53) 60.0 33.3 15.7 ? ?
? DLBCL 22.6(12/53) 58.3 33.3 25.0 ? ?
? 淋巴浆细胞型淋巴瘤 5.6(3/53) - - - ? ?
表3 PGL预后影响因素的多因素分析
图1 手术根治度对原发性胃淋巴瘤生存预后的影响
图2 组织分型对原发性胃淋巴瘤生存预后的影响
图3 Ann Arbor分期对原发性胃淋巴瘤生存预后的影响
表4 MALT与DLBCL患者的预后影响相关性因素分析
病例资料 MALT[%(例/例)] 5年生存率(%) χ2 P DLBCL[%(例/例)] 5年生存率(%) χ2 P
性别 ? ? 4.800 0.028 ? ? 2.088 0.148
? 67.6(23/34) 39.8 ? ? 50.0(6/12) 0.0 ? ?
? 32.4(11/34) 77.9 ? ? 50.0(6/12) 33.3 ? ?
年龄 ? ? 2.559 0.110 ? ? 0.102 0.749
? ≥60岁 38.2(13/34) 69.2 ? ? 75.0(9/12) 22.2 ? ?
? <60岁 61.8(21/34) 85.7 ? ? 25.0(3/12) - ? ?
肿瘤位置 ? ? 0.055 0.997 ? ? 3.083 0.379
? 上、上中 32.4(11/34) 49.1 ? ? 25.0(3/12) - ? ?
? 中、中下 23.5(8/34) 40.0 ? ? 16.7(2/12) - ? ?
? 下部 35.3(12/34) 62.5 ? ? 41.6(5/12) 20.0 ? ?
? 全胃 8.8(3/34) - ? ? 16.7(2/12) - ? ?
既往胃肠道疾病史 ? ? 0.169 0.681 ? ? 8.659 0.003
? 32.4(11/34) 56.1 ? ? 16.7(2/12) - ? ?
? 67.6(23/34) 59.5 ? ? 83.3(10/12) 30.0 ? ?
淋巴管瘤栓 ? ? 0.431 0.511 ? ? 1.647 0.199
? 37.9(11/29) 40.9 ? ? 30.0(3/10) - ? ?
? 62.1(18/29) 70.5 ? ? 70.0(7/10) 14.3 ? ?
术后治疗 ? ? 1.038 0.308 ? ? 0.422 0.516
? 21.9(7/32) 85.7 ? ? 25.0(3/12) - ? ?
? 78.1(25/32) 53.6 ? ? 75.0(9/12) 22.2 ? ?
胃切除范围 ? ? 3.786 0.151 ? ? 0.767 0.681
? 胃近端切除 29.0(9/31) 38.9 ? ? 18.2(2/11) - ? ?
? 胃远端切除 51.6(16/31) 77.3 ? ? 36.4(4/11) 25 ? ?
? 全胃切除 19.4(6/31) 30.0 ? ? 45.4(5/11) 20 ? ?
手术根治度 ? ? 18.189 0.000 ? ? 1.054 0.305
? R0切除 74.2(23/31) 77.7 ? ? 63.6(7/11) 28.6 ? ?
? 姑息切除 25.8(8/31) 12.5 ? ? 36.4(4/11) 0.00 ? ?
侵犯脏器 ? ? 17.455 <0.001 ? ? 0.232 0.630
? 24.2(8/33) 0.00 ? ? 45.4(5/11) 0.00 ? ?
? 75.8(25/33) 70.8 ? ? 54.6(6/11) 33.3 ? ?
肿瘤大小 ? ? 0.893 0.345 ? ? 0.325 0.569
? ≥5.0 cm 44.4(12/27) 48.6 ? ? 80.0(8/10) 12.5 ? ?
? <5.0 cm 55.6(15/27) 59.8 ? ? 20.0(2/10) - ? ?
Ann Arbor分期 ? ? 14.252 0.003 ? ? 0.089 0.766
? ⅠE期 52.9(18/34) 67.6 ? ? 16.7(2/12) - ? ?
? ⅡE期 23.5(8/34) 60.6 ? ? 83.3(10/12) 37.7 ? ?
? ⅢE期 2.9(1/34) - ? ? 0(0/12) - ? ?
? ⅣE期 20.6(7/34) 14.3 ? ? 0(0/12) - ? ?
[1]
Hwang JP, Lim I, Byun BH, et al. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma [J]. Nucl Med Commun, 2016, 37(12): 1267-1272.
[2]
Al-Akwaa AM, Siddiqui N, Al-Mofleh IA. Primary gastric lymphoma [J]. World J Gastroenterol, 2004, 10(1): 5-11.
[3]
D′Amore F, Christensen BE, Thorling K, et al. Incidence, presenting features and prognosis of low-grade B-cell non-Hodgkin′s lymphomas. Population-based data from a Danish lymphoma registry [J]. Leuk Lymphoma, 1993, 12(1-2): 69-77.
[4]
Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96) [J]. J Clin Oncol, 2005, 23(28): 7050-7059.
[5]
Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis [J]. Br J Surg, 1961, 49: 80-89.
[6]
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms [J]. 2016, 127(20): 2375-2390.
[7]
Kong SH, Kim MA, Park DJ, et al. Clinicopathologic features of surgically resected primary gastric lymphoma [J]. World J Gastroenterol, 2004, 10(8): 1103-1109.
[8]
Zullo A, Hassan C, Andriani A, et al. Primary low-grade and high-grade gastric MALT-lymphoma presentation [J]. J Clin Gastroenterol, 2010, 44(5): 340-344.
[9]
Vanis N, Mesihovic R, Ibricevic L, et al. Predictive value of endoscopic ultrasound in diagnosis and staging of primary gastric lymphoma [J]. Coll Antropol, 2013, 37 Suppl 1: 291-297.
[10]
Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? [J]. Radiology, 2004, 232(3): 823-829.
[11]
Zukerberg LR, Ferry JA, Southern JF, et al. Lymphoid infiltrates of the stomach. Evaluation of histologic criteria for the diagnosis of low-gradegastric lymphoma on endoscopic biopsy specimens [J]. Am J Surg Pathol, 1990, 14(12): 1087-1099.
[12]
Koh YW, Park C, Yoon DH, et al. Prognostic significance of COX-2expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma [J]. Am J Surg Pathol, 2013, 37(8): 1242-1251.
[13]
Wang YG, Zhao LY, Liu CQ, et al. Clinical characteristics and prognostic factors of primary gastric lymphoma: A retrospective study with 165 cases [J]. Medicine (Baltimore), 2016, 95(31): e4250.
[14]
He M, Gao L, Zhang S, et al. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL [J]. Gastric Cancer, 2014, 17(3): 431-441.
[15]
Bairey O, Shacham-Abulafia A, Shpilberg O, et al. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor [J]. Hematol Oncol, 2016, 34(4): 184-192.
[16]
Lim EL, Trinh DL, Scott DW, et al. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients [J]. Genome Biol, 2015, 16: 18.
[17]
Zheng Z, Li X, Zhu Y, et al. Prognostic significance of miRNA in patients with diffuse large B-cell lymphoma: a meta-analysis [J]. Cell Physiol Biochem, 2016, 39(5): 1891-1904.
[18]
Sbitti Y, Ismaili N, Bensouda Y, et al. Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy? [J]. J Hematol Oncol, 2010, 3: 23.
[19]
Selcukbiricik F, Tural D, Elicin O, et al. Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease [J]. ISRN Oncol, 2012, 2012: 951816.
[20]
Ferreri AJM, Cordio S, Paro S, et al. Therapeutic Management of Stage I–II High-Grade Primary Gastric Lymphomas [J]. Oncology, 1999, 56(4): 274-282.
[21]
Ge Z, Liu Z, Hu X. Anatomic distribution, clinical features, and survival data of 87 cases primary gastrointestinal lymphoma [J]. World J Surg Oncol, 2016, 14: 85.
[22]
Yoon SS, Coit DG, Portlock CS, et al. The diminishing role of surgery in the treatment of gastric lymphoma [J]. Ann Surg, 2004, 240(1): 28-37.
[23]
张浩然,翟云芝,楼建军, 等. 非霍奇金淋巴瘤患者血清β2-微球蛋白和CA125检测的意义[J]. 中国当代医药, 2014, 21(23): 51-53.
[24]
Raderer M, Wohrer S, Kiesewetter B, et al. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up [J]. Ann Hematol, 2015, 94(6): 969-973.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[5] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[6] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[7] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[8] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[9] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[10] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[11] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[12] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[13] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
阅读次数
全文


摘要